Moxonidine-SZ, 0.2 mg 60 pcs

How to take, the dosage

Ingestion, regardless of meals. In most cases, the initial dose of Moxonidine-SZ is 0.2 mg/day. The maximum single dose is 0.4 mg. The maximum daily dose to be divided into 2 doses is 0.6 mg.

An individual adjustment of the daily dose is necessary depending on the patient’s tolerance to the current therapy.

Dose adjustment is not required for patients with hepatic insufficiency.

The starting dose for patients with moderate to severe renal impairment is 0.2 mg/day.

If necessary and if well tolerated, the daily dose can be increased to a maximum of 0.4 mg.

Interaction

The co-administration of moxonidine with other hypotensive agents leads to additive effects.

Tricyclic antidepressants may decrease the effectiveness of centrally acting hypotensive agents, therefore it is not recommended to take them together with moxonidine.

Moxonidine may increase the effects of tricyclic antidepressants, tranquilizers, ethanol, sedatives and hypnotics.

Moxonidine may moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may increase the sedative effect of benzodiazepine derivatives when prescribed concomitantly.

Moxonidine is excreted by tubular secretion. Therefore, its interaction with other drugs excreted by tubular secretion cannot be excluded.

Beta-adrenoblockers increase bradycardia, the severity of negative and dromotropic effects.

Special Instructions

If it is necessary to cancel beta-adrenoblockers and Moxonidine taken simultaneously, the beta-adrenoblockers should be cancelled first and only after several days Moxonidine. There is currently no evidence that discontinuation of Moxonidine leads to an increase in BP. However, it is not recommended to stop Moxonidine abruptly; instead, the dose should be gradually reduced over a period of two weeks. During treatment, avoid alcohol consumption. During treatment it is necessary to monitor heart rate and electrocardiography regularly.

The effect on the ability to drive and operate machinery

The effect of Moxonidine on the ability to drive vehicles or operate machinery has not been studied. However, taking into account the possibility of dizziness and somnolence patients should be careful when engaging in potentially dangerous activities requiring increased attention, such as driving vehicles or operating machinery requiring increased concentration.

.

Contraindications

– hypersensitivity to the active substance and other components of the drug;

– sinus node weakness syndrome;

– pronounced bradycardia (resting heart rate less than 50 beats/min.

– atrioventricular block of II and III degree;

– expressed arrhythmia;

– acute and chronic heart failure (functional class III-IV according to NYHA classification);

– concurrent use with tricyclic antidepressants (see “Interaction with other antidepressants”).

– concomitant use of tricyclic antidepressants (see section “Interaction with other medicinal products”);

– severe renal insufficiency (CKR less than 30 ml/min);

– hemodialysis;

– lactation period;

– hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption;

– age older than 75 years;

– under 18 years of age (due to lack of safety and effectiveness data).

Cautions

Particular caution should be exercised when using moxonidine in patients with atrioventricular block of degree I (risk of bradycardia); severe coronary artery disease, severe coronary heart disease or unstable angina (insufficient experience of use), chronic heart failure, severe hepatic insufficiency, with impaired renal function (CKG greater than 30 ml/min).

.

Side effects

The frequency of adverse effects listed below was determined accordingly as follows: very frequently (≥1/10); frequently (≥1/100, <1/10); infrequently (≥1/1000, <1/100), including individual reports.

CNS side:often – headache*, dizziness (vertigo), somnolence; infrequent – fainting*.

Systems:infrequent – marked decrease in BP, orthostatic hypotension*, bradycardia.

Gastrointestinal disorders:very often – dry mucous membrane of the mouth; often – diarrhea, nausea, vomiting, dyspepsia.

Skin and subcutaneous tissue:often – skin rash, itching; infrequently – angioedema.

Mental disorders:often – insomnia; infrequently – nervousness.

Hearing organ and labyrinth disorders: infrequently – tinnitus.

Skeletal, muscular and connective tissue disorders:often – back pain; infrequently – neck pain.

General disorders and disorders at the site of administration:often – asthenia; infrequently – peripheral edema.

.

Overdose

There have been reports of several nonfatal overdoses when doses up to 19.6 mg were used at one time.

Symptoms:Headache, sedation, marked BP decrease, dizziness, asthenia, bradycardia, dry oral mucosa, vomiting, increased fatigue, epigastric pain, respiratory depression and impaired consciousness. In addition, transient BP elevation, tachycardia and hyperglycemia are also possible, as has been shown in several high-dose animal studies.

Treatment:There is no specific antidote to the drug. In cases of marked BP decrease, it may be necessary to restore blood pressure by administration of fluids and dopamine (by injection). Bradycardia may be stopped with atropine (injection). In severe cases of overdose, it is recommended to carefully control impaired consciousness and avoid respiratory depression. Alpha-adrenoceptor antagonists may reduce or eliminate the paradoxical hypertensive effects of moxonidine overdose. Moxonidine is slightly excreted by hemodialysis.

Similarities

Moxonidine, Moxonitex, Tensotran, Physiotensis, Moxarel